13F Holdings
中文EN

RMTG Regenerative Medical Technology Group Inc.

Retail-Retail Stores, NEC · OTC · SEC CIK 1760026 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY94.3%
TTM net income YoY-155.5%
TTM EPS YoY-55.6%
Revenue 3-yr CAGR66.0%
Net income 3-yr CAGR—

Margins

Gross margin59.8%
Operating margin0.5%
Net margin-101.2%
FCF margin-6.2%
EBITDA margin4.3%

Returns

ROE—
ROA-184.4%
ROIC (approx.)—
Asset turnover1.82x

Leverage & solvency

Liabilities / assets771.0%
Debt / equity—
Current ratio0.05x
Interest coverage0.00x

Cash quality & payout

Operating cash flow / net income-0.03x
Accruals ratio-189.6%
Payout ratio—
Capex / revenue9.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$5.10M$4.11M$2.41M$1.53M$437,887
Cost of revenue$2.29M$1.28M$734,285$653,256$287,750
Gross profit$2.81M$2.82M$1.68M$876,967$150,137
SG&A expense$1.12M$798,316$752,527$424,258$149,374
Operating income-$867,162$81,181-$715,226——
Interest expense$7.45M$5.64M$6.49M—$2.72M
Income tax-$1.64M-$1.16M-$2.06M-$1.16M-$2.71M
Net income-$7.81M-$5.56M-$9.81M-$5.51M-$12.88M
EBITDA-$586,095$301,740-$405,124——
EPS (basic)-0.62-0.44-0.79-0.45-1.12
EPS (diluted)-0.62-0.44-0.79-0.45-1.12
Weighted avg. shares (diluted)12.63M12.53M12.45M12.22M11.48M
Balance sheet
Cash & equivalents$956,718$1.17M$530,540$1.65M$2.98M
Receivables$43,815$22,605$23,956$49,766$17,256
Inventory$159,277$10,115———
Current assets$1.22M$1.25M$574,996$1.69M$3.02M
PP&E, net$870,759$451,703$359,303$186,269$22,909
Goodwill$1.68M$1.68M$1.68M$5.81M$5.81M
Intangibles$61,464$159,004$256,544$354,084$451,624
Total assets$4.49M$3.82M$2.88M$8.08M$9.31M
Current liabilities$38.13M$28.97M$22.25M$12.00M$4.22M
Total liabilities$40.54M$31.18M$24.67M$20.06M$16.06M
Shareholders' equity-$36.05M-$27.36M-$21.80M-$11.98M-$6.76M
Shares outstanding13.14M12.54M12.49M12.44M12.09M
Cash flow statement
Operating cash flow-$706,519$850,699-$419,199-$1.11M-$9.88M
Capital expenditure$602,583$215,419$385,596$198,428—
Free cash flow-$1.31M$635,280-$804,795-$1.31M—
Investing cash flow-$602,583-$215,419-$385,596-$198,428$666,467
Financing cash flow$1.10M—-$309,850-$20,776$12.15M
Depreciation & amortization$281,067$220,559$310,102$152,739$40,858

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.